Deutsche Bank Cuts Biogen Estimates

Analyst Dennis Harp thinks the European delay of Amevive will push back the drug's launch to 2006

Deutsche Bank lowered its estimates on Biogen (BGEN ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.